Navigation Links
AMDL Announces Closing of Private Offering
Date:12/24/2007

TUSTIN, Calif., Dec. 24 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that it has conducted the closing of its combined Regulation D/Regulation S private unit offering of 2,007,508 shares of common stock and warrants to purchase 1,003,755 shares of common stock, generating net proceeds of approximately $5,433,000. The shares of AMDL common stock were sold at $3.09 per share and the four year warrants included in the units are exercisable at $4.74 per share. Warrants to purchase an additional 200,751 shares were issued to AMDL's placement agents at the same exercise price. AMDL agreed to file a registration statement within 60 days of the closing to register the resale of the shares of common stock and the shares issuable on exercise of the warrants included in the units and the placement agent warrants. Spencer Clarke, LLC, a FINRA member broker dealer, acted as AMDL's principal placement agent for sales in the United States, and Galileo Asset Management, S.A., a member of the Association Romande des Intermediaries Financier, acted as AMDL's placement agent for sales outside of the United States.

Gary L. Dreher, President of AMDL, said: "The reception to the offering was gratifying under the current economic climate. These funds provide some of the additional working capital we need to expand Jade Pharmaceutical Inc.'s new business opportunities and product development efforts in China and for our other general working capital needs."

About AMDL

AMDL, Inc., headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its products can be obt
'/>"/>

SOURCE AMDL, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Muncie, IN (PRWEB) July 25, 2014 ... Administration (FAA) has granted a 60-day extension for the ... of the Special Rule for Model Aircraft established by ... Act of 2012. The 60-day extension establishes the new ... the United States Department of Transportation/FAA notice published in ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... forces worldwide rely on sophisticated equipment, trained personnel, ... public areas against terrorist attacks. A revolutionary new ... to make their job much easier. , The ... of Tel Aviv University ,s School of Chemistry ... by the Herzliya company Tracense, picks up the ...
(Date:7/24/2014)... natural and synthetic processes prefer to settle into ... energyit is within the realm of non-equilibrium conditions ... changes in energy and phases, such as temperature ... allow humans to regulate their body temperature, airplanes ... seismic activity. , But even though these ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2
... 2 According to the National Institute of Health, 40 percent ... stage of diabetic retinopathy. Diabetic retinopathy, damage to the retina ... in people with diabetes and is one of the most feared ... patients who,ve had diabetes for 10 years or more will experience ...
... , ... that a new market research report is available in ... Trends , http://www.reportlinker.com/p0164494/Chromium---Global-Market-Trends.html , Worldwide ... while growth in aerospace and industrial gas turbine markets ...
... PLYMOUTH, Mass., Dec. 1 Harvest Technologies Corp. ( ... 60-patient clinical trial conducted at Sri Ramachandra Medical Center ... treat patients with non-reconstructable Critical Limb Ischemia (CLI). Sri ... based in Chennai, India and one of the largest ...
Cached Biology Technology:Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... Institutes of Health announced today that it will fund ... -- chemical modifications to genes that result from diet, ... to specific human diseases and biological processes. ... as part of the NIH Roadmap for Medical Research,s ...
... University is being honored for one of its programs ... institute,s intern program has received the roundtable group,s Most ... award, as the best pollution prevention project/program. The honor ... The award is presented based on a program,s ...
... LA JOLLA, Calif., September 15, 2009 -- Researchers ... have discovered that reactive oxygen species, such as ... in forming invadopodia, cellular protrusions implicated in cancer ... professor and director of the Tumor Microenvironment Program ...
Cached Biology News:NIH funds grantees focusing on epigenomics of human health and disease 2NIH funds grantees focusing on epigenomics of human health and disease 3NIH funds grantees focusing on epigenomics of human health and disease 4K-State Pollution Prevention Institute's intern program named best 2Reactive oxygen's role in metastasis 2
Mouse monoclonal [3576] to Yellow Fever Virus ( Abpromise for all tested applications). Antigen: Tissue / cell preparation...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA ...
6X Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Ideally suited for resolving DNA and RNA 10-1000 bases especially PCR products ranging from 100-1000 bp. Gelling temp. (4%) 27C Melting temperature 65C. EEO: 0.10 Rnase/Dnase: none detected...
Biology Products: